Literature DB >> 11135436

5q11, 8p11, and 10q22 are recurrent chromosomal breakpoints in prostate cancer cell lines.

Y Pan1, W O Lui, N Nupponen, C Larsson, J Isola, T Visakorpi, U S Bergerheim, S Kytölä.   

Abstract

Prostate cancer cell lines have been widely used as model systems characterizing pathogenetic, functional, and therapeutic aspects of prostate cancer development. However, their chromosomal compositions are poorly characterized. In this study, five prostate cancer cell lines-TSU-Pr1, JCA-1, NCI-H660, ALVA-31, and PPC-1-were investigated by G-banding, comparative genomic hybridization (CGH), and spectral karyotyping. The results were combined with our previous findings in the prostate cancer cell lines PC-3, DU145, and LNCaP. By comparative genomic hybridization (CGH), the most frequent losses were observed at 13q, 8p, 9p, and 4q, whereas gains were most commonly seen at 8q, 10q, and 18p. The composite karyotypes were characterized by multiple numerical and structural chromosomal aberrations. Recurrent breakpoints at 5q11, 8p11, and 10q22 were observed to participate in deletion and translocation events in five of the cell lines, suggesting the importance of tumor suppressor and/or oncogenes in these regions. ALVA-31 and PPC-1 shared nine identical derivative chromosomes, two of which have also been detected in PC-3. In addition, the identification of the same homozygous deletion at D10S541 and of an identical TP53 gene mutation in all three cell lines suggests a common origin of these cell lines. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11135436

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  9 in total

1.  The impact of genomic alterations on the transcriptome: a prostate cancer cell line case study.

Authors:  J Chaudhary; M Schmidt
Journal:  Chromosome Res       Date:  2006-07-12       Impact factor: 5.239

2.  Upregulated MT1-MMP/TIMP-2 axis in the TSU-Pr1-B1/B2 model of metastatic progression in transitional cell carcinoma of the bladder.

Authors:  Christine L Chaffer; Bonnie Dopheide; Daniel R McCulloch; Allan B Lee; Jane M Moseley; Erik W Thompson; Elizabeth D Williams
Journal:  Clin Exp Metastasis       Date:  2005       Impact factor: 5.150

3.  Lack of an additive effect between the deletions of Klf5 and Nkx3-1 in mouse prostatic tumorigenesis.

Authors:  Changsheng Xing; Xiaoying Fu; Xiaodong Sun; Jin-Tang Dong
Journal:  J Genet Genomics       Date:  2013-05-02       Impact factor: 4.275

4.  Cyclin E and FGF8 are downstream cell growth regulators in distinct tumor suppressor effects of ANXA7 in hormone-resistant cancer cells of breast versus prostate origin.

Authors:  A Bera; X-M Leighton; H Pollard; M Srivastava
Journal:  Trends Cancer Res       Date:  2018

5.  miR-449a causes Rb-dependent cell cycle arrest and senescence in prostate cancer cells.

Authors:  Emily J Noonan; Robert F Place; Shashwati Basak; Deepa Pookot; Long-Cheng Li
Journal:  Oncotarget       Date:  2010-09

6.  Efficient elimination of cancer cells by deoxyglucose-ABT-263/737 combination therapy.

Authors:  Ryuji Yamaguchi; Edith Janssen; Guy Perkins; Mark Ellisman; Shinichi Kitada; John C Reed
Journal:  PLoS One       Date:  2011-09-19       Impact factor: 3.240

7.  Aberrations of TACC1 and TACC3 are associated with ovarian cancer.

Authors:  Brenda Lauffart; Mary M Vaughan; Roger Eddy; David Chervinsky; Richard A DiCioccio; Jennifer D Black; Ivan H Still
Journal:  BMC Womens Health       Date:  2005-05-26       Impact factor: 2.809

8.  Prognostic factors in prostate cancer.

Authors:  A Buhmeida; S Pyrhönen; M Laato; Y Collan
Journal:  Diagn Pathol       Date:  2006-04-03       Impact factor: 2.644

9.  Epidermal Growth Factor Is Essential for the Maintenance of Novel Prostate Epithelial Cells Isolated From Patient-Derived Organoids.

Authors:  Katia Cheaito; Hisham F Bahmad; Hiba Jalloul; Ola Hadadeh; Hiba Msheik; Albert El-Hajj; Deborah Mukherji; Mohamed Al-Sayegh; Wassim Abou-Kheir
Journal:  Front Cell Dev Biol       Date:  2020-10-29
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.